Abstract
Twist Bioscience Corp will report fiscal second-quarter results on May 4, 2026, Pre-Market, with investors watching for revenue acceleration, margin resilience, and updated guidance relative to prior targets.
Market Forecast
Based on currently compiled forecasts, Twist Bioscience Corp is expected to deliver revenue of 107.66 million US dollars for the fiscal second quarter, implying 17.03% year-over-year growth, with an estimated adjusted EPS of -0.48 reflecting a 17.08% year-over-year improvement in per-share loss and an estimated EBIT of -30.73 million US dollars, a 15.36% year-over-year improvement. The company’s full-year revenue outlook communicated after its prior quarterly update called for 435.00 million to 440.00 million US dollars, providing a supportive backdrop for quarterly cadence even as no explicit gross margin or net income guidance was issued for the quarter.
The core portfolio of revenue streams is expected to remain anchored by the Therapeutics and Diagnostics businesses, with a continued mix shift toward higher-value workflows and steady reorder activity from existing accounts. The most promising near-term growth vector is Therapeutics, which generated 37.23 million US dollars last quarter and is positioned to benefit from expanded discovery offerings; year-over-year segment growth was not disclosed.
Last Quarter Review
In fiscal first quarter 2026, Twist Bioscience Corp reported revenue of 103.70 million US dollars, a 16.89% year-over-year increase, with a gross profit margin of 52.05%, a GAAP net loss attributable to common shareholders of 30.51 million US dollars, a net profit margin of -29.42%, and adjusted EPS of -0.50, improving 5.66% year-over-year.
A notable highlight following the quarter was the reaffirmed and constructive full-year revenue outlook of 435.00 million to 440.00 million US dollars for fiscal 2026, implying healthy sequential progression through the year. At the business-line level, the portfolio’s mix remained concentrated in Therapeutics at 37.23 million US dollars and Diagnostics at 35.32 million US dollars, which together represented roughly 70% of revenue; overall company revenue rose 16.89% year-over-year.
Current Quarter Outlook
Main business trajectory
Quarter to quarter, the current setup suggests a measured acceleration in top-line performance, with forecasts pointing to 107.66 million US dollars, a modest sequential lift from 103.70 million US dollars and a 17.03% increase versus the year-ago fiscal second quarter. The revenue mix is expected to continue favoring higher-complexity orders in Therapeutics and Diagnostics, which typically support better unit economics than smaller, transactional orders. While the company has not provided an explicit gross margin target for fiscal second quarter 2026, the prior quarter’s 52.05% gross margin provides a useful reference point; stability or incremental improvement would materially influence operating leverage and the translation of revenue growth into EBIT progression.
Expense discipline will remain under scrutiny. With an estimated EBIT of -30.73 million US dollars (a 15.36% year-over-year improvement), the market is looking for continued narrowing of losses without impairing the cadence of product and platform investments. If management sustains cost controls while preserving R&D and commercial capacity, the earnings trajectory should continue to improve, even in the absence of a near-term shift to profitability. The quality of revenue will also be a focus: recurring orders from established accounts, longer-duration contracts, and mix toward higher-throughput and discovery-oriented workflows would all support margin durability and predictability of cash needs across the remainder of the fiscal year.
Most promising business: Therapeutics-focused discovery and workflows
Within the reported business mix, Therapeutics delivered 37.23 million US dollars last quarter, edging out Diagnostics as the largest single contributor. The strategic rationale for naming Therapeutics as the most promising near-term driver is grounded in the broadening of discovery services and workflows that can expand the addressable customer use cases and deepen account penetration. The announced licensing arrangement for the B-Body bispecific antibody platform provides an additional lever to increase the scope and throughput of complex antibody discovery campaigns. This kind of platform augmentation can translate into richer project pipelines, greater multi-quarter visibility, and a higher proportion of comprehensive engagements over time.
Although year-over-year growth for the Therapeutics segment was not disclosed, the qualitative indicators point to sustained demand for complex DNA constructs, libraries, and discovery services where technical depth and end-to-end workflow integration are valued. The key to turning those engagements into measurable financial progress this quarter lies in execution: faster cycle times from order to delivery, higher utilization of production capacity, and efficient allocation of resources to higher-margin projects. If the company can align operational capacity with the intake of larger and more complex orders, the expected incremental revenue this quarter could yield an outsized contribution to gross profit dollars, reinforcing the path to smaller operating losses as the year progresses.
Stock price drivers: revenue beat/raise potential, margin sustainment, and guidance cadence
Three variables are likely to exert the greatest influence on the share price on and immediately after May 4, 2026. The first is the relationship between reported revenue and the 107.66 million US dollar estimate; a top-line beat would support the full-year range of 435.00 million to 440.00 million US dollars and potentially open the door to a higher internal cadence for the back half of fiscal 2026. Conversely, any sign of slower order intake or timing-related deferrals could prompt investors to recalibrate second-half expectations even if the full-year target remains intact.
The second variable is margin performance. Investors will watch whether gross margin can hold near the prior quarter’s 52.05% or show incremental improvement. The drivers here include product and project mix, production throughput, and any residual impact from input costs and logistics. Marginal gains in gross margin can translate into proportionally larger improvements in EBIT and EPS because operating expenses are relatively fixed over a near-term horizon. If adjusted EPS loss narrows near the -0.48 estimate alongside better gross profit dollars, it would underscore operating leverage consistent with a glidepath toward smaller losses over the next several quarters.
The third variable is the tone and specificity of management’s guidance, especially commentary on order trends, funnel conversion, and the pacing required to achieve the full-year revenue range. The market will be attentive to any updates on bookings quality, larger multi-quarter project wins, and potential expansion of the discovery portfolio following the platform licensing actions announced earlier in the year. Clarity on cash usage and the anticipated trajectory of operating losses over the next two quarters would also be impactful, as it shapes investor confidence in the company’s ability to balance growth investment with measured progress toward breakeven.
Analyst Opinions
Bullish vs. bearish ratio: 100% bullish, 0% bearish. The prevailing stance among the analysts tracked in recent months has been supportive of the revenue trajectory and the company’s path of incremental loss reduction, with a notable Buy rating reiterated by Barclays. In that note, analyst Luke Sergott maintained a Buy rating and set a 39.00 US dollars price target, highlighting confidence that execution on the current roadmap can sustain top-line growth and margin consistency. This endorsement is consistent with the broader tone of commentary following the fiscal first-quarter print, which emphasized that the company’s revenue delivery, improved loss profile, and reaffirmed full-year guidance aligned with expectations.
The bullish case centers on three primary assertions. First, the company has delivered two consecutive quarters of double-digit year-over-year revenue growth, and consensus implies that trend continues in the fiscal second quarter with a projected 17.03% increase to 107.66 million US dollars. Second, the prior quarter’s gross margin of 52.05% sets a constructive baseline that, if sustained, would reinforce EBIT improvement; consensus modeling implies a 15.36% year-over-year improvement in EBIT to -30.73 million US dollars, consistent with gradual operating leverage. Third, the expanded discovery offering in Therapeutics—bolstered by platform licensing—improves the opportunity set for larger and more complex projects, which analysts view as supportive of higher-quality growth and better gross profit dollar generation.
Analysts also underscore the importance of guidance cadence for the remainder of fiscal 2026. The previously communicated full-year revenue range of 435.00 million to 440.00 million US dollars provides a clear measuring stick against which quarterly updates can be assessed. If management reports a revenue figure at or above the 107.66 million US dollars expectation and pairs it with constructive commentary on order intake and production throughput, the bullish narrative anticipates that estimates could remain stable to higher for the back half of the year. Conversely, if revenue timing pushes some projects into later quarters but the full-year range is reiterated with consistent margin commentary, most bulls suggest that the market would be inclined to look through transitory timing effects.
In summary, the majority analyst view heading into May 4, 2026 is that Twist Bioscience Corp is positioned to deliver year-over-year revenue growth, maintain gross margin in a healthy zone, and continue narrowing losses on an adjusted basis. The Buy rating and target from a well-known investment bank reinforce that stance, with the near-term debate hinging on the magnitude of any top-line beat, the sustainability of margin performance around the prior 52.05% level, and the consistency of guidance relative to the 435.00 million to 440.00 million US dollars full-year framework.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments